Truist Financial Raises DaVita (NYSE:DVA) Price Target to $165.00

DaVita (NYSE:DVA) had its price target hoisted by Truist Financial from $150.00 to $165.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has a hold rating on the stock.

DVA has been the topic of several other research reports. Barclays boosted their price objective on shares of DaVita from $133.00 to $150.00 and gave the stock an equal weight rating in a report on Monday, May 6th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the company an underperform rating in a report on Wednesday, August 7th. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a buy rating in a report on Thursday, August 8th. TD Cowen upped their target price on DaVita from $139.00 to $150.00 and gave the company a hold rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded shares of DaVita from a strong-buy rating to a buy rating in a research note on Saturday, June 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus target price of $157.00.

DaVita Price Performance

NYSE DVA opened at $153.99 on Tuesday. The stock has a 50-day simple moving average of $141.05 and a 200 day simple moving average of $135.90. DaVita has a twelve month low of $71.51 and a twelve month high of $155.56. The stock has a market capitalization of $13.50 billion, a PE ratio of 17.50, a P/E/G ratio of 0.87 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.08 earnings per share. Research analysts anticipate that DaVita will post 9.9 EPS for the current year.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares of the company’s stock, valued at $36,299,008.35. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On DaVita

Large investors have recently modified their holdings of the stock. Blue Trust Inc. raised its position in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the last quarter. Wedmont Private Capital raised its position in shares of DaVita by 6.0% during the second quarter. Wedmont Private Capital now owns 1,701 shares of the company’s stock worth $241,000 after acquiring an additional 96 shares during the last quarter. First Trust Direct Indexing L.P. lifted its stake in shares of DaVita by 3.9% during the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock valued at $358,000 after acquiring an additional 98 shares during the period. Quent Capital LLC boosted its holdings in DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after acquiring an additional 101 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in DaVita by 18.8% in the first quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock worth $91,000 after purchasing an additional 104 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.